{"title":"THE IMPORTANCE OF ANALGO-SEDATION IN THE PATIENT WITH SERIOUS PELVIC AND SPINE TRAUMA DURING TRANSPORT","authors":"Florica BĂGESCU-DRUGĂ POP","doi":"10.31925/farmacia.2023.5.11","DOIUrl":null,"url":null,"abstract":"This prospective, randomised study aimed to assess the efficacy of ketamine/propofol (K/P) compared to the commonly used fentanyl/midazolam (F/M) combination in providing analgesia for patients with severe pelvic and spinal trauma. The study, conducted over 30 months on 154 patients, found that the K/P group experienced significantly lower perceived pain levels, as measured on the numerical pain scale, when compared to the F/M group (p < 0.0001). Additionally, patients in the K/P group achieved adequate sedation with an average Ramsay scale score of 3.1, while the F/M group had a more profound sedation with a score of 5.5 (p < 0.0001). Furthermore, the study demonstrated that analgesia with K/P significantly improved the physiological severity score (PSS) (p < 0.0001) and resulted in a notably lower incidence of oxygen desaturation, with only one patient experiencing this in the K/P group compared to 16 patients in the F/M group (p = 0.0003). These findings suggest that co-administration of low-dose ketamine and propofol provides safe and effective sedation and analgesia, both in the emergency department and pre-hospital settings. The study highlights the importance of adequate pain management in severe trauma cases and emphasizes the potential advantages of using the K/P combination over F/M, particularly due to the reduced risk of oxygen desaturation and the more moderate level of sedation achieved with K/P. These results underscore the potential clinical utility of this approach in improving the overall care and outcomes of patients with severe pelvic and spinal trauma","PeriodicalId":12344,"journal":{"name":"FARMACIA","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31925/farmacia.2023.5.11","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
This prospective, randomised study aimed to assess the efficacy of ketamine/propofol (K/P) compared to the commonly used fentanyl/midazolam (F/M) combination in providing analgesia for patients with severe pelvic and spinal trauma. The study, conducted over 30 months on 154 patients, found that the K/P group experienced significantly lower perceived pain levels, as measured on the numerical pain scale, when compared to the F/M group (p < 0.0001). Additionally, patients in the K/P group achieved adequate sedation with an average Ramsay scale score of 3.1, while the F/M group had a more profound sedation with a score of 5.5 (p < 0.0001). Furthermore, the study demonstrated that analgesia with K/P significantly improved the physiological severity score (PSS) (p < 0.0001) and resulted in a notably lower incidence of oxygen desaturation, with only one patient experiencing this in the K/P group compared to 16 patients in the F/M group (p = 0.0003). These findings suggest that co-administration of low-dose ketamine and propofol provides safe and effective sedation and analgesia, both in the emergency department and pre-hospital settings. The study highlights the importance of adequate pain management in severe trauma cases and emphasizes the potential advantages of using the K/P combination over F/M, particularly due to the reduced risk of oxygen desaturation and the more moderate level of sedation achieved with K/P. These results underscore the potential clinical utility of this approach in improving the overall care and outcomes of patients with severe pelvic and spinal trauma
期刊介绍:
FARMACIA publishes original research papers, invited topical reviews and editorial commentaries and news, with emphasis on conceptual novelty and scientific quality. Main research areas are focused on: pharmacology, toxicology, medicinal chemistry, biopharmacy, drug design, drug delivery, personalized medicine, nanostructures, nutraceuticals, biochemistry and biotechnology. Manuscripts submitted to the Journal are only accepted after the peer review precess. The papers should have not been published in any other journal. The recommendations of the Declaration of Helsinki, for humans, and the International guidelines as accepted principles for the use of experimental animals should be followed.